Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.
Jason G. Andrade,Jean Champagne,Marc Dubuc,Marc W. Deyell,Atul Verma,Laurent Macle,Peter Leong-Sit,Paul Novak,Mariano Badra-Verdu,John Sapp,Iqwal Mangat,Clarence Khoo,Christian Steinberg,Matthew T. Bennett,Anthony S.L. Tang,Paul Khairy,Ratika Parkash,Peter Guerra,Katia Dyrda,Lena Rivard,Normand Racine,Lawrence Sterns,Rick Leather,Colette Seifer,Umjeet Jolly,Jean-Marc Raymond,Jean-Francois Roux,Isabelle Nault,Jean-Francois Sarrazin,Krishnan Ramanathan,Christopher Cheung,Christopher Fordyce,Jimmy McKinney,Christina Luong,Jacques Rizkallah,Paul Angaran,Andrew Ha,Benedict Glover,Allan Skanes,Lorne Gula
DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042622
IF: 37.8
2019-11-26
Circulation
Abstract:Background: Advanced generation ablation technologies have been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence following atrial fibrillation (AF) ablation. Methods: We randomly assigned 346 patients with drug-refractory paroxysmal AF to contactforce guided RF ablation (CF-RF ablation, 115), 4-minute cryoballoon ablation (CRYO-4, 115), or 2-minute cryoballoon ablation (CRYO-2, 116). Follow-up was 12 months. The primary outcome was time to first documented recurrence of symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia) between days 91 and 365 post ablation, or a repeat ablation procedure at any time. Secondary endpoints included freedom from symptomatic arrhythmia, and AF burden. All patients received an implantable loop recorder. Results: One-year freedom from atrial tachyarrhythmia defined by continuous rhythm monitoring, was 53.9%, 52.2%, and 51.7% with CF-RF, CRYO-4, and CRYO-2, respectively; P=0.87. One-year freedom from symptomatic atrial tachyarrhythmia defined by continuous rhythm monitoring, was 79.1%, 78.2%, and 73.3% with CF-RF, CRYO-4, and CRYO-2, respectively; P=0.26. Compared to the pre-ablation monitoring period, AF burden was reduced by a median of 99.3% (IQR 67.8-100.0%) with CF-RF, 99.9% (IQR 65.3-100.0%) with CRYO4, and 98.4% (IQR 56.2-100.0%) with CRYO-2 (P=0.36). Serious adverse events occurred in 2 patients in CF-RF (2.6%), 6 patients in CRYO-4 (5.3%), and 7 patients in CRYO-2 (6.0%), with no significant difference between groups (P=0.24). The CF-RF group had a significantly longer procedure duration but significantly shorter fluoroscopy exposure (P<0.001 vs. cryoballoon groups). Conclusions: In this multicenter, randomized, single-blinded trial, contact-force RF ablation and two different regiments of cryoballoon ablation resulted in no difference in one-year efficacy, which was 53% by time to first recurrence but >98% burden reduction as assessed by continuous cardiac rhythm monitoring.
cardiac & cardiovascular systems,peripheral vascular disease